Immunovaccine Inc. is a clinical-stage biopharmaceutical company. The Company discovers and develops products that activate the immune system to treat cancer and infectious diseases. The Company has a product platform that is used to create highly immunogenic vaccines. The Company develops cancer immunotherapies and infectious disease vaccines based on its DepoVax platform, a formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. The Company has advanced two T cell activation therapies for cancer through Phase I human clinical trials. One of its cancer vaccine candidates is being tested in a Phase II trial in lymphoma. The Company is also advancing an infectious disease pipeline, including vaccines for respiratory syncytial virus (RSV) and anthrax.